AVEO Oncology Announces Participation at Two Upcoming Investor Conferences
January 06 2021 - 7:00AM
Business Wire
AVEO Oncology (Nasdaq: AVEO) today announced that Michael
Bailey, president and chief executive officer of AVEO, will
participate in two upcoming virtual investor conferences:
H.C. Wainwright Virtual BioConnect Conference Date:
Monday, January 11 – Thursday, January 14
B. Riley Virtual Oncology Investor Conference Date:
Wednesday, January 20 Time: 1:30 PM Eastern Time
A replay of the pre-recorded H.C. Wainwright presentation can be
accessed on Monday, January 11, 2021 in the investors section of
the Company’s website at www.aveooncology.com, and a live webcast
of the B. Riley presentation can be accessed in the same section of
the Company’s website. A replay of the webcasts will be archived
for 30 days following the presentation date.
About AVEO Pharmaceuticals, Inc.
AVEO is an oncology-focused biopharmaceutical company committed
to delivering medicines that provide a better life for cancer
patients. AVEO’s strategy is to focus its resources toward
development and commercialization of its product candidates in
North America, while leveraging partnerships to support development
and commercialization in other geographies. AVEO’s lead candidate,
tivozanib, is approved as FOTIVDA® in the European Union and other
countries in the EUSA territory for the treatment of adult patients
with advanced renal cell carcinoma. Tivozanib is being studied in
the TIVO-3 trial, which is supporting a regulatory submission of
tivozanib in the U.S. seeking marketing approval as a treatment for
relapsed or refractory renal cell carcinoma. AVEO has previously
reported promising early clinical data on ficlatuzumab (anti-HGF
mAb) in head and neck cancer, acute myeloid leukemia and pancreatic
cancer and is conducting a randomized Phase 2 confirmatory clinical
trial of ficlatuzumab in head and neck cancer. AVEO’s earlier-stage
pipeline includes several monoclonal antibodies in oncology
development, including AV-203 (anti-ErbB3 mAb), AV-380 (anti-GDF15
mAb) and AV-353 (anti-Notch 3 mAb). AVEO is committed to creating
an environment of diversity and inclusion as a foundation for
innovation.
Cautionary Note Regarding Forward-Looking Statements
This press release contains forward-looking statements of AVEO
within the meaning of the Private Securities Litigation Reform Act
of 1995 that involve substantial risks and uncertainties. All
statements, other than statements of historical fact, contained in
this press release are forward-looking statements. Actual results
or events could differ materially due to a number of important
factors, including risks discussed in the section titled “Risk
Factors” in AVEO’s most recent Annual Report on Form 10-K, its
quarterly reports on Form 10-Q and its other filings with the SEC.
The forward-looking statements in this press release represent
AVEO’s views as of the date of this press release. AVEO anticipates
that subsequent events and developments may cause its views to
change. While AVEO may elect to update these forward-looking
statements at some point in the future, it specifically disclaims
any obligation to do so. You should, therefore, not rely on these
forward-looking statements as representing AVEO’s views as of any
date other than the date of this press release
View source
version on businesswire.com: https://www.businesswire.com/news/home/20210106005199/en/
AVEO Contact: David Pitts, Argot Partners (212) 600-1902
aveo@argotpartners.com
AVEO Pharmaceuticals (NASDAQ:AVEO)
Historical Stock Chart
From May 2024 to Jun 2024
AVEO Pharmaceuticals (NASDAQ:AVEO)
Historical Stock Chart
From Jun 2023 to Jun 2024